Bryan S Barker1,2, Matteo Ottolini1, Jacy L Wagnon3, Rachel M Hollander3, Miriam H Meisler3, Manoj K Patel1,2. 1. Department of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia, U.S.A. 2. Neuroscience Graduate Program, University of Virginia Health System, Charlottesville, Virginia, U.S.A. 3. Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, U.S.A.
Abstract
OBJECTIVE: SCN8A encephalopathy (early infantile epileptic encephalopathy; EIEE13) is caused by gain-of-function mutations resulting in hyperactivity of the voltage-gated sodium channel Nav 1.6. The channel is concentrated at the axon initial segment (AIS) and is involved in establishing neuronal excitability. Clinical features of SCN8A encephalopathy include seizure onset between 0 and 18 months of age, intellectual disability, and developmental delay. Seizures are often refractory to treatment with standard antiepileptic drugs, and sudden unexpected death in epilepsy (SUDEP) has been reported in approximately 10% of patients. In a recent study, high doses of phenytoin were effective in four patients with SCN8A encephalopathy. In view of this observation, we have investigated the relationship between the functional effect of the SCN8A mutation p.Ile1327Val and its response to phenytoin. METHODS: The mutation was introduced into the Scn8a cDNA by site-directed mutagenesis. Channel activity was characterized in transfected ND7/23 cells. The effects of phenytoin (100 μm) on mutant and wild-type (WT) channels were compared. RESULTS: Channel activation parameters were shifted in a hyperpolarizing direction in the mutant channel, whereas inactivation parameters were shifted in a depolarizing direction, increasing Na channel window current. Macroscopic current decay was slowed in I1327V channels, indicating an impairment in the transition from open state to inactivated state. Channel deactivation was also delayed, allowing more channels to remain in the open state. Phenytoin (100 μm) resulted in hyperpolarized activation and inactivation curves as well as greater tonic block and use-dependent block of I1327V mutant channels relative to WT. SIGNIFICANCE: SCN8A - I1327V is a gain-of-function mutation with altered features that are predicted to increase neuronal excitability and seizure susceptibility. Phenytoin is an effective inhibitor of the mutant channel and may be of use in treating patients with gain-of-function mutations of SCN8A. Wiley Periodicals, Inc.
OBJECTIVE:SCN8Aencephalopathy (early infantile epilepticencephalopathy; EIEE13) is caused by gain-of-function mutations resulting in hyperactivity of the voltage-gated sodium channel Nav 1.6. The channel is concentrated at the axon initial segment (AIS) and is involved in establishing neuronal excitability. Clinical features of SCN8Aencephalopathy include seizure onset between 0 and 18 months of age, intellectual disability, and developmental delay. Seizures are often refractory to treatment with standard antiepileptic drugs, and sudden unexpected death in epilepsy (SUDEP) has been reported in approximately 10% of patients. In a recent study, high doses of phenytoin were effective in four patients with SCN8Aencephalopathy. In view of this observation, we have investigated the relationship between the functional effect of the SCN8A mutation p.Ile1327Val and its response to phenytoin. METHODS: The mutation was introduced into the Scn8a cDNA by site-directed mutagenesis. Channel activity was characterized in transfected ND7/23 cells. The effects of phenytoin (100 μm) on mutant and wild-type (WT) channels were compared. RESULTS: Channel activation parameters were shifted in a hyperpolarizing direction in the mutant channel, whereas inactivation parameters were shifted in a depolarizing direction, increasing Na channel window current. Macroscopic current decay was slowed in I1327V channels, indicating an impairment in the transition from open state to inactivated state. Channel deactivation was also delayed, allowing more channels to remain in the open state. Phenytoin (100 μm) resulted in hyperpolarized activation and inactivation curves as well as greater tonic block and use-dependent block of I1327V mutant channels relative to WT. SIGNIFICANCE: SCN8A - I1327V is a gain-of-function mutation with altered features that are predicted to increase neuronal excitability and seizure susceptibility. Phenytoin is an effective inhibitor of the mutant channel and may be of use in treating patients with gain-of-function mutations of SCN8A. Wiley Periodicals, Inc.
Authors: Raimund I Herzog; Theodore R Cummins; Farshid Ghassemi; Sulayman D Dib-Hajj; Stephen G Waxman Journal: J Physiol Date: 2003-07-03 Impact factor: 5.182
Authors: Ulvi Vaher; Margit Nõukas; Tiit Nikopensius; Mart Kals; Tarmo Annilo; Mari Nelis; Katrin Ounap; Tiia Reimand; Inga Talvik; Pilvi Ilves; Andres Piirsoo; Enn Seppet; Andres Metspalu; Tiina Talvik Journal: J Child Neurol Date: 2013-12-18 Impact factor: 1.987
Authors: Nicholas J Hargus; Ellen C Merrick; Aradhya Nigam; Christopher L Kalmar; Aparna R Baheti; Edward H Bertram; Manoj K Patel Journal: Neurobiol Dis Date: 2010-10-11 Impact factor: 5.996
Authors: Maxime G Blanchard; Marjolein H Willemsen; Jaclyn B Walker; Sulayman D Dib-Hajj; Stephen G Waxman; Marjolijn C J Jongmans; Tjitske Kleefstra; Bart P van de Warrenburg; Peter Praamstra; Joost Nicolai; Helger G Yntema; René J M Bindels; Miriam H Meisler; Erik-Jan Kamsteeg Journal: J Med Genet Date: 2015-02-27 Impact factor: 6.318
Authors: Jacy L Wagnon; Bryan S Barker; James A Hounshell; Charlotte A Haaxma; Amy Shealy; Timothy Moss; Sumit Parikh; Ricka D Messer; Manoj K Patel; Miriam H Meisler Journal: Ann Clin Transl Neurol Date: 2015-12-21 Impact factor: 4.511
Authors: Ragna S Boerma; Kees P Braun; Marcel P H van den Broek; Maarten P H van de Broek; Frederique M C van Berkestijn; Marielle E Swinkels; Eveline O Hagebeuk; Dick Lindhout; Marjan van Kempen; Maartje Boon; Joost Nicolai; Carolien G de Kovel; Eva H Brilstra; Bobby P C Koeleman Journal: Neurotherapeutics Date: 2016-01 Impact factor: 7.620
Authors: Luis F Lopez-Santiago; Yukun Yuan; Jacy L Wagnon; Jacob M Hull; Chad R Frasier; Heather A O'Malley; Miriam H Meisler; Lori L Isom Journal: Proc Natl Acad Sci U S A Date: 2017-02-13 Impact factor: 11.205
Authors: Kameryn M Butler; Cristina da Silva; Yuval Shafir; James D Weisfeld-Adams; John J Alexander; Madhuri Hegde; Andrew Escayg Journal: Epilepsy Res Date: 2016-11-06 Impact factor: 3.045
Authors: Erin M Baker; Christopher H Thompson; Nicole A Hawkins; Jacy L Wagnon; Eric R Wengert; Manoj K Patel; Alfred L George; Miriam H Meisler; Jennifer A Kearney Journal: Epilepsia Date: 2018-05-21 Impact factor: 5.864
Authors: Ryan S Sprissler; Jacy L Wagnon; Rosie K Bunton-Stasyshyn; Miriam H Meisler; Michael F Hammer Journal: Exp Neurol Date: 2016-11-09 Impact factor: 5.330
Authors: Julia Oyrer; Snezana Maljevic; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou; Christopher A Reid Journal: Pharmacol Rev Date: 2018-01 Impact factor: 25.468
Authors: Eric R Wengert; Anusha U Saga; Payal S Panchal; Bryan S Barker; Manoj K Patel Journal: Neuropharmacology Date: 2019-07-03 Impact factor: 5.250
Authors: Bryan S Barker; Aradhya Nigam; Matteo Ottolini; Ronald P Gaykema; Nicholas J Hargus; Manoj K Patel Journal: Neurobiol Dis Date: 2017-08-30 Impact factor: 5.996
Authors: Rosie K A Bunton-Stasyshyn; Jacy L Wagnon; Eric R Wengert; Bryan S Barker; Alexa Faulkner; Pravin K Wagley; Kritika Bhatia; Julie M Jones; Marissa R Maniaci; Jack M Parent; Howard P Goodkin; Manoj K Patel; Miriam H Meisler Journal: Brain Date: 2019-02-01 Impact factor: 13.501